Physician profile
Peter Stempniewicz
NPI 1386058881
$2,195.56
in general payments reported to CMS, 2019-2025
23 companies · $409 in 2025
The $409 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,002 · 2020: $32.19 · 2022: $170 · 2023: $284 · 2024: $298 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $394.58 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $264.46 | 2019-2025 | |
| Pfizer INC. | $206.77 | 2019-2025 | |
| Edwards Lifesciences Corporation | $168.00 | 2025 | |
| Abiomed | $137.14 | 2023 | Impella |
| Amgen INC. | $136.27 | 2019 | |
| Amarin Pharma, INC. | $120.68 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.45 | 2019-2025 | Lifevest |
| W. L. Gore & Associates, INC. | $102.38 | 2019 | |
| Impulse Dynamics (USA) INC. | $97.66 | 2025 | Optimizer |
| Astrazeneca Pharmaceuticals Lp | $89.73 | 2019-2025 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $71.75 | 2019-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.01 | 2023-2024 | Jardiance |
| Corcept Therapeutics | $48.32 | 2023-2024 | Korlym |
| Ascensia Diabetes Care US INC. | $32.43 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $25.93 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $24.14 | 2024 | Uptravi, Opsumit |
| Janssen Pharmaceuticals, INC | $23.91 | 2023 | Xarelto |
| Recordati_rare_diseases_inc. | $21.66 | 2025 | Isturisa |
| Novo Nordisk INC | $21.00 | 2024 | Rybelsus, Ozempic |
| Xeris Pharmaceuticals, INC. | $17.81 | 2023 | Gvoke Hypopen |
| Aimmune Therapeutics, INC. | $17.41 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $13.07 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Stempniewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.